Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of nivolumab alone or
in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring
mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA.
Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and
safe doses and schedules have been determined.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Bristol-Myers Squibb Cancer Research Institute, New York City Personal Genome Diagnostics